CollPlant Biotechnologies (NASDAQ:CLGN) Given “Buy” Rating at D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $14.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 416.80% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Trading Down 3.2 %

NASDAQ CLGN opened at $2.71 on Thursday. The firm’s fifty day moving average price is $3.50 and its two-hundred day moving average price is $3.96. CollPlant Biotechnologies has a 1 year low of $2.56 and a 1 year high of $6.75. The firm has a market capitalization of $31.03 million, a P/E ratio of -1.76 and a beta of 1.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLGN. Benjamin Edwards Inc. acquired a new stake in shares of CollPlant Biotechnologies during the third quarter worth $112,000. AMH Equity Ltd increased its position in CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after acquiring an additional 17,295 shares during the period. Renaissance Technologies LLC bought a new position in CollPlant Biotechnologies during the fourth quarter worth about $38,000. Finally, Wells Fargo & Company MN raised its stake in CollPlant Biotechnologies by 110.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares in the last quarter. 21.69% of the stock is owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.